深圳市卫光生物制品股份有限公司关于对外投资的自愿性披露公告

Core Viewpoint - The company, Shenzhen Weiguang Biological Products Co., Ltd., is making a voluntary disclosure regarding its investment in establishing a public service platform for cell and gene therapy in Shenzhen, with a total investment of 40 million RMB, representing 40% of the project company’s equity [1][21]. Investment Overview - The company plans to jointly invest with Shenzhen Shenye Biological Pharmaceutical Industry Development Co., Ltd., Shenzhen Cell Valley Biomedical Co., Ltd., and Shenzhen Saiqiao Biological Innovation Technology Co., Ltd. to establish Shenzhen Xihe Life Technology Co., Ltd. (tentative name) [1][26]. - The initial registered capital of the project company is 100 million RMB, with the company contributing 40 million RMB, which accounts for 1.81% of the company's latest audited net assets [1][23]. Partner Companies - Shenzhen Shenye Biological Pharmaceutical Industry Development Co., Ltd. - Type: Limited liability company - Registered capital: 30 million RMB - Business scope includes investment activities, consulting services, and cell technology research and application [2][3]. - Shenzhen Cell Valley Biomedical Co., Ltd. - Type: Limited liability company (foreign investment, non-independent) - Registered capital: 12.914 million RMB - Business scope includes cell technology research, medical device sales, and various consulting services [4][5]. - Shenzhen Saiqiao Biological Innovation Technology Co., Ltd. - Type: Limited liability company (wholly owned by a legal person) - Registered capital: 10 million RMB - Business scope includes pharmaceutical equipment development, laboratory instruments, and medical device production [8][9]. Project Details - The project aims to create a public service platform for cell and gene therapy (CGT) that focuses on marketization and standardization, addressing key challenges in the industry such as high production costs and lack of unified standards [10][21]. - The project will establish a production and testing system that meets GMP standards, facilitating technology transfer and creating a sustainable business ecosystem [10][22]. Strategic Importance - This investment aligns with national policies for the development of the biopharmaceutical industry and aims to enhance the CGT industry in Shenzhen, contributing to the region's industrial core position [21][22]. - The project represents a strategic move for the company to expand from blood products into the forefront of biomedicine, fostering new business growth and enhancing competitive advantages [22][23].